Norma Hellas Testosterone Enanthate 250mg/ ampule

Norma Testosterone Enanthate

Testosterone Enanthate Norma

Injectable solution

Testosterone Enanthate 250 mg

DCI active substance

Testosterone

COMPOSITION

1 ml solution contains the active substance: testosterone enanthate 250 mg. Excipients: benzyl alcohol, benzyl benzoate, peach oil.

PHARMACEUTICAL FORM

Solution for injection.

DESCRIPTION OF THE MEDICINAL PRODUCT

Oily, transparent, light yellow-to-yellow color solution with a characteristic smell.

PHARMACOTERAPEUTICS AND ATC code Androgenic hormone, G03B A03.

PHARMACOLOGICAL PROPERTIES

Pharmacodynamic properties

Testosterone enanthate is a testosterone ester. Testosterone is the primary androgenic hormone synthesized and released by the testicles. It is responsible for the growth and development of male sexual organs and secondary sexual characteristics (prostate, seminar, and penis and scrotum maturation), male hair distribution (face, pubis, and chest), laryngeal development, body muscles, and fat distribution.  Retains nitrogen, sodium, potassium, and phosphorus, increases anabolism and reduces protein catabolism. An early increase in testosterone plasma concentration during the prepubertal period causes epifizelir closure and growth arrest. Stimulates the production of erythropoietin and erythrocytes. By feedback mechanism, it inhibits the secretion of luteinizing hormones and folliculostimulating hypo visions and causes the suppression of spermatogenesis. In women, they inhibit gonadrophysiopharyngeal function, ovary function, mammary glandular, emitter atrophy. Due to its estrogen antagonistic action, it is used in the treatment of uterine meiosis, endometriosis, and breast cancer.  It manifests beneficial action during the climacteric period.

Pharmacokinetic properties
Testosterone enanthate is slowly absorbed. Maximum plasma concentration is achieved over 72 hours after intramuscular administration. Duration of action 2-4 weeks. In the blood, about 98% of testosterone is coupled to a specific fraction of globulin, which binds testosterone and estradiol. Biotransformation occurs in the liver up to 17 ketosteroids, which after conjugation with glucuronic or sulfuric acid is eliminated with urine (about 90%). Approximately 6% of the absorbed preparation is removed with the feces in free form.

THERAPEUTIC INDICATIONS

In men – substitution hormone treatment in the deficiencies caused by testosterone deficiency:

• Retaining sex pasteurization;
• Eunucoidism, non-development of genitals – impotence of hormone origin;
• Hypopiate;
• Male climax symptoms (decreased libido and physical and intellectual activity);
• Poscastrational syndrome (androgen deficiency after castration);
• Osteoporosis caused by androgen insufficiency.

In women

• heeprestrogenemia, functional bleeding;
• myoma uterine;
• endometriosis;
• menopause (in combination with estrogen) – breast cancer;

DOSE AND METHOD OF ADMINISTRATION

Intramuscularly deep. The dose is established individually depending on the disease, sex, age, clinical efficacy. Usually, adults are administered intramuscularly 50-200 mg once in 2-4 weeks. It is not recommended to exceed the 400 mg dose per month. The duration of treatment is established individually. In hypogonadism in men like eunuchoidism, the recommended doses are 50-400 mg every 2-4 weeks. In the case of sexual maturation, 50 to 200 mg every 2-4 weeks is administered for 4-6 months.  In breast cancer inoperable in women: 200-400 mg every 2-4 weeks. The preparation is not given intravenously!

CONTRAINDICATIONS

Individual hypersensitivity to the preparation; prostate or breast carcinoma; prostate hyperplasia with prostate symptoms with symptoms of mucus disorder, nephrotic or nephrotic nephritic phase, edema, hypercalcemia, liver function disorder, diabetes mellitus, heart or coronary insufficiency, myocardial infarction in past atherosclerosis in elderly men, pregnancy, breastfeeding.

More information about test enanthate from Norma Hellas you can find here.